GlassScriptPhysician profile
Joseph Patrick Crowley
NPI 1093330375
$11,194.52
in general payments reported to CMS, 2019-2025
26 companies · $2,906 in 2025
The $2,906 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $485 · 2023: $2,898 · 2024: $4,905 · 2025: $2,906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,607.79 |
| Education | $101.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,870.76 | 2022-2025 | |
| Alkermes, INC. | $1,374.59 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $1,131.11 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $1,055.34 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,024.90 | 2022-2025 | Caplyta |
| Tris Pharma INC | $951.23 | 2023-2025 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $674.60 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $615.89 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $452.69 | 2022-2025 | Trintellix |
| Corium, LLC | $412.94 | 2023-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $329.54 | 2022-2024 | |
| Noven Therapeutics, LLC | $215.94 | 2024 | Xelstrym, Secuado |
| E.R. Squibb & Sons, L.L.C. | $182.47 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $173.23 | 2022-2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $147.74 | 2023-2024 | Spravato |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $131.11 | 2024 | Relexxii |
| Collegium Pharmaceutical, INC. | $123.77 | 2025 | Jornay Pm |
| Indivior INC. | $68.28 | 2023-2024 | Perseris |
| Almatica Pharma LLC | $59.04 | 2024-2025 | Loreev Xr |
| Supernus Pharmaceuticals, INC. | $43.91 | 2023-2024 | Qelbree, Qelbree |
| Tempus Ai, INC | $39.31 | 2024 | |
| Idorsia Pharmaceuticals US INC | $31.18 | 2023 | Quviviq |
| Neurocrine Biosciences, INC. | $30.14 | 2025 | |
| Sunovion Pharmaceuticals INC. | $21.38 | 2022 | |
| Eisai INC. | $19.28 | 2022 | |
| Bausch Health US, LLC | $14.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Crowley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.